Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2018

View Archived Issues

FDA accepts SIGA Technologies' NDA for TPOXX

Daiichi Sankyo studies DS-1205c with osimertinib for metastatic or unresectable EGFR-mutant NSCLC

New phase II umbrella trial studies novel agents for the management of relapsed ovarian cancer

V ClinBio acquires 49.98% equity stake in Cellix Bio

Rebinyn launched in the U.S.for the treatment of hemophilia B

Sanofi files tender offer for Bioverativ

Columbia University divulges novel CKI-epsilon inhibitors

Q Biomed receives exclusive option for glaucoma biomarker GDF-15

FDA priority review granted for antimalarial tafenoquine

New RET kinase inhibitors identified at Blueprint Medicines

Roche discovers new serine protease HTRA1 inhibitors

Shanghai Yingli Pharmaceutical presents new TGF-beta receptor type-1 inhibitors

Novel ACKR3 antagonists patented by Idorsia Pharmaceuticals

Therapix Biosciences clarifies regulatory pathway for THX-110

ABAC Therapeutics identifies novel antibacterials

AstraZeneca announces pipeline highlights of fourth quarter 2017

SPK-8011 shown safe and effective for hemophilia A

GlaxoSmithKline reviews milestones of fourth quarter 2017

Implantable device allows photodynamic therapy for tumors deep in the body

Vifor prepares to begin phase I trial of oral ferroportin inhibitor VIT-2763

Significant reductions in LDL-cholesterol seen with MGL-3196 in phase II tiral

uniQure presents further clinical data on AMT-060 for hemophilia B

Rexahn Pharmaceuticals to collaborate with Zhejiang Haichang Biotechnology on RX-0201

Lonza Pharma & Biotech and Denali Therapeutics partner on biologics

Bristol-Myers Squibb offers overview of fourth quarter 2017

FDA grants orphan drug designation to Xeris' ready-to-use, liquid-stable glucagon

Phase III trials of peficitinib in rheumatoid arthritis meet primary endpoints

Fujifilm and Takeda establish regenerative medicine collaboration to treat heart failure

Treatment begins in phase II SHINE-1 study of scar reduction with EB-001

FDA approves Zytiga with prednisone for metastatic high-risk castration-sensitive prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...